US20230083203A1 - Non-invasive test to predict response to therapy in colorectal cancer patients - Google Patents
Non-invasive test to predict response to therapy in colorectal cancer patients Download PDFInfo
- Publication number
- US20230083203A1 US20230083203A1 US18/046,565 US202218046565A US2023083203A1 US 20230083203 A1 US20230083203 A1 US 20230083203A1 US 202218046565 A US202218046565 A US 202218046565A US 2023083203 A1 US2023083203 A1 US 2023083203A1
- Authority
- US
- United States
- Prior art keywords
- patient
- treatment
- colorectal cancer
- therapy
- therapy regimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 46
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 27
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 27
- 238000012360 testing method Methods 0.000 title description 16
- 238000000034 method Methods 0.000 claims abstract description 38
- 238000011282 treatment Methods 0.000 claims description 40
- 229960000397 bevacizumab Drugs 0.000 claims description 31
- 239000000090 biomarker Substances 0.000 claims description 30
- 108700028369 Alleles Proteins 0.000 claims description 22
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 230000004083 survival effect Effects 0.000 claims description 12
- 230000000259 anti-tumor effect Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 30
- 238000004458 analytical method Methods 0.000 abstract description 5
- 230000035772 mutation Effects 0.000 description 47
- 210000001519 tissue Anatomy 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 18
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 15
- 238000012163 sequencing technique Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 101150040459 RAS gene Proteins 0.000 description 11
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 11
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 10
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 10
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 10
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 10
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 10
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 9
- 101150076031 RAS1 gene Proteins 0.000 description 9
- 238000002512 chemotherapy Methods 0.000 description 9
- 102000016914 ras Proteins Human genes 0.000 description 9
- 102100030708 GTPase KRas Human genes 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 206010061289 metastatic neoplasm Diseases 0.000 description 7
- 230000006698 induction Effects 0.000 description 6
- 230000001394 metastastic effect Effects 0.000 description 6
- 238000011269 treatment regimen Methods 0.000 description 6
- 238000007481 next generation sequencing Methods 0.000 description 5
- 238000002203 pretreatment Methods 0.000 description 5
- 206010069754 Acquired gene mutation Diseases 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 102100039788 GTPase NRas Human genes 0.000 description 4
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 4
- 230000008092 positive effect Effects 0.000 description 4
- 230000037439 somatic mutation Effects 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 101150105104 Kras gene Proteins 0.000 description 2
- 101150063858 Pik3ca gene Proteins 0.000 description 2
- 101150080074 TP53 gene Proteins 0.000 description 2
- 101150048834 braF gene Proteins 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000036438 mutation frequency Effects 0.000 description 2
- 108700025694 p53 Genes Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000004326 stimulated echo acquisition mode for imaging Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 102100028914 Catenin beta-1 Human genes 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 description 1
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 description 1
- 102100022334 Dihydropyrimidine dehydrogenase [NADP(+)] Human genes 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 101710105178 F-box/WD repeat-containing protein 7 Proteins 0.000 description 1
- 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 102100024185 G1/S-specific cyclin-D2 Human genes 0.000 description 1
- 102100037859 G1/S-specific cyclin-D3 Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102100025334 Guanine nucleotide-binding protein G(q) subunit alpha Human genes 0.000 description 1
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 description 1
- 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 1
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 1
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 1
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 description 1
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 description 1
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 description 1
- 101000902632 Homo sapiens Dihydropyrimidine dehydrogenase [NADP(+)] Proteins 0.000 description 1
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 description 1
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 101000980741 Homo sapiens G1/S-specific cyclin-D2 Proteins 0.000 description 1
- 101000738559 Homo sapiens G1/S-specific cyclin-D3 Proteins 0.000 description 1
- 101000857888 Homo sapiens Guanine nucleotide-binding protein G(q) subunit alpha Proteins 0.000 description 1
- 101001014590 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Proteins 0.000 description 1
- 101001014594 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Proteins 0.000 description 1
- 101001072407 Homo sapiens Guanine nucleotide-binding protein subunit alpha-11 Proteins 0.000 description 1
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 1
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 1
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101001014610 Homo sapiens Neuroendocrine secretory protein 55 Proteins 0.000 description 1
- 101001120056 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit alpha Proteins 0.000 description 1
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 1
- 101000797903 Homo sapiens Protein ALEX Proteins 0.000 description 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101000771237 Homo sapiens Serine/threonine-protein kinase A-Raf Proteins 0.000 description 1
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 description 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 1
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 description 1
- 102000004034 Kelch-Like ECH-Associated Protein 1 Human genes 0.000 description 1
- 108090000484 Kelch-Like ECH-Associated Protein 1 Proteins 0.000 description 1
- 108010068342 MAP Kinase Kinase 1 Proteins 0.000 description 1
- 108010068353 MAP Kinase Kinase 2 Proteins 0.000 description 1
- 229910015837 MSH2 Inorganic materials 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 102000008071 Mismatch Repair Endonuclease PMS2 Human genes 0.000 description 1
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 101150097381 Mtor gene Proteins 0.000 description 1
- 102000007561 NF-E2-Related Factor 2 Human genes 0.000 description 1
- 108010071382 NF-E2-Related Factor 2 Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000012850 Patched-1 Receptor Human genes 0.000 description 1
- 108010065129 Patched-1 Receptor Proteins 0.000 description 1
- 102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 102100029437 Serine/threonine-protein kinase A-Raf Human genes 0.000 description 1
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 description 1
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 102100029152 UDP-glucuronosyltransferase 1A1 Human genes 0.000 description 1
- 101710205316 UDP-glucuronosyltransferase 1A1 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000011123 anti-EGFR therapy Methods 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 101150059244 pfs gene Proteins 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the invention relates to the field of oncology. More specifically, the invention relates to the field of nucleic acid-based testing of cancer patients.
- mCRC metastatic colorectal cancer
- the invention is a method for identifying a colorectal cancer patient in stage II, III or IV as likely to positively respond to a therapy regimen with increased progression-free survival (PFS), the method comprising the steps of: providing a cell-free blood sample obtained from the patient; determining the sequence of at least a portion of each of the biomarkers listed in Table 1; measuring the frequency of mutant alleles; identifying the patient as likely to positively respond to a therapy regimen if the frequency of mutant alleles is below a median documented for colorectal cancer patients at the same stage; or identifying the patient as not likely to positively respond to a therapy regimen if the frequency of mutant alleles is above a median documented for colorectal cancer patients at the same stage.
- PFS progression-free survival
- the patient can be a stage II, III or IV colorectal cancer patient.
- the method further comprises a step of administering therapy if the patient is identified as likely to positively respond to a therapy regimen.
- the therapy regimen may be treatment with FOLFOXIRI-bevacizumab or treatment FOLFOX-bevacizumab.
- the treatment with FOLFOXIRI-bevacizumab may be concurrent or sequential.
- the invention is a method for identifying a colorectal cancer patient in stage II, III or IV as likely to positively respond to a therapy regimen with increased progression-free survival (PFS), the method comprising the steps of: providing a cell-free blood sample obtained from the patient; determining the mutation status of one or more genes selected from KRAS, BRAF, TP53 and PIK3CA; identifying the patient as likely to positively respond to a therapy regimen if the genes KRAS, BRAF and PIK3CA are wild-type and gene TP53 is mutant; or identifying the patient as not likely to positively respond to a therapy regimen if the genes KRAS, BRAF and PIK3CA are mutant and gene TP53 is wild-type.
- the therapy regimen is selected from concurrent and sequential FOLFOXIRI-bevacizumab.
- the invention is a method of treatment of a colorectal cancer patient in stage II, III or IV comprising the steps of: providing a cell-free blood sample obtained from the patient; determining the sequence of at least a portion of each of the biomarkers listed in Table 1; measuring the frequency of mutant alleles; identifying the patient as likely to positively respond to a therapy regimen if the frequency of mutant alleles is below a median documented for colorectal cancer patients at the same stage; or identifying the patient as not likely to positively respond to a therapy regimen if the frequency of mutant alleles is above a median documented for colorectal cancer patients at the same stage; administering the therapy regimen to the patient identified as likely to positively respond to the therapy.
- the patient may be a stage II, III or IV colorectal cancer patient.
- the therapy regimen is selected from concurrent and sequential FOLFOXIRI-bevacizumab.
- the invention is a computer system designed to implement an algorithm for detecting mutations in a sample from colorectal cancer patient, wherein the algorithm analyses sequencing data on biomarkers from Table 1 and contains one or more steps selected from mutation detection, mutation frequency scoring, controlling for germ-line variation, error correction and final determination whether the sample is mutation-positive.
- FIG. 1 illustrates the design of the therapy response prediction study.
- FIG. 2 illustrates Kaplan Meier graphs comparing treatment of RAS wild-type patients.
- FIG. 3 illustrates Kaplan Meier graphs comparing treatment of TP53 mutant patients.
- FIG. 4 illustrates Kaplan Meier graphs comparing treatment outcomes of patients with different mutation burdens (mutant allele frequencies, AF).
- RFS Recurrence Free Survival
- TTR Total Time to Recurrence for a patient.
- OS is used herein to describe the time of Overall Survival for a patient.
- CAPP-Seq is used herein to describe a method of analyzing cell-free tumor DNA in a patient disclosed in U.S. patent application Ser. Nos. 14/209,807, 14/774,518 and International Application Ser. No. PCT/US2015/049838 titled “Identification and Use of Circulating Tumor Markers.”
- R0 patient is used herein to describe a patient having clear histological margins from resected tissue.
- R1 patient is used herein to describe a patient having microscopic residual disease in surgically resected tissue.
- circulating tumor DNA circulating tumor DNA
- ctDNA circulating tumor DNA
- biomarker is used herein to describe a nucleotide sequence that contains information relevant to the biological or clinical phenomenon.
- the information may be a mutation status of the sequence.
- the biomarker can be a gene (including coding sequence, regulatory sequence, intron or a splice site) or an intergenic region.
- the clinical phenomenon can be the presence of malignant cells, e.g., tumor cells in a patient's sample.
- the invention describes methods of selecting a treatment regimen for a colorectal cancer (CRC) patient including a metastatic colorectal cancer (mCRC) patient.
- CRC colorectal cancer
- mCRC metastatic colorectal cancer
- the invention uses a biomarker panel to identify somatic mutations and mutation burden in cancer-related genes by next-generation sequencing (NGS).
- NGS next-generation sequencing
- the invention utilized a blood sample from a patient.
- the sample can include any fraction of blood, e.g., serum or plasma, which contains cell-free DNA including circulating tumor DNA (cfDNA or ctDNA).
- the sample is taken serially at various times during treatment, e.g., before and after surgery or before, after and during a chemotherapy regimen.
- tissue sample is available for comparison with the blood sample.
- the tissue or blood sample can be collected by a suitable means that preserves the DNA therein, including formalin-fix paraffin-embedding (FFPE), fresh frozen tissue or blood tissue collected in a preservative medium.
- FFPE formalin-fix paraffin-embedding
- the invention utilizes a biomarker panel, including a gene panel or a mutation panel or a somatic variant panel.
- the mutations may include single-nucleotide variations (SNVs), deletions and insertions (in-dels) that correspond to on-sense missense and frame-shift mutations if they occur in the coding regions of genes.
- SNVs single-nucleotide variations
- in-dels deletions and insertions
- Other types of mutations include gene fusions and translocations. The selection, size and content of such panels has been described e.g., in U.S. patent application Ser. Nos. 14/209,807, 14/774,518 and International app. No.
- the invention includes determining the sequence of the biomarkers in the panel, e.g., the genes listed in Table 1. In some embodiments, the entire sequence of a gene is determined. In other embodiments, the entire coding sequence of a gene is determined. In other embodiments, only the sequence of a portion of the gene known to undergo mutagenesis in cancer is determined. In yet other embodiments, the biomarker is not associated with a coding sequence but is associated with a regulatory sequence or a sequence of unknown function known to be mutated in human tumors.
- the sequence of a biomarker can be determined via any suitable method known in the art.
- the suitable method would have sufficient accuracy, e.g., sensitivity and specificity to detect rare sequences with a low rate of errors.
- the sequencing method includes an error correction step, such as use of molecular barcodes, error stereotyping and other chemical or computation methods of error suppression as described e.g., in see the patent applications “Identification and Use of Circulating Tumor Markers”, supra.
- the sequencing method may include a massively parallel sequencing method, including an array based sequencing (Illumina, San Diego, Calif.), an emulsion-based sequencing (ThermoFisher, Waltham, Mass.) an optical measurement based sequencing (Pacific BioSciences, Menlo Park, Calif.) or a nanopore-based sequencing (Roche Sequencing Solutions, Santa Clara, Calif.).
- array based sequencing Illumina, San Diego, Calif.
- emulsion-based sequencing ThermoFisher, Waltham, Mass.
- optical measurement based sequencing Pacific BioSciences, Menlo Park, Calif.
- nanopore-based sequencing Roche Sequencing Solutions, Santa Clara, Calif.
- the invention utilizes a biomarker panel, such as AVENIO• ctDNA Analysis Kit (Roche Sequencing Solutions, Inc., Pleasanton, Calif.) that is capable of analyzing the blood of patients after surgery to identify whether patients have circulating tumor DNA (ctDNA).
- a biomarker panel such as AVENIO• ctDNA Analysis Kit (Roche Sequencing Solutions, Inc., Pleasanton, Calif.) that is capable of analyzing the blood of patients after surgery to identify whether patients have circulating tumor DNA (ctDNA).
- ctDNA circulating tumor DNA
- a panel of 77 genes listed in Table 1 is used.
- the mutation status is determined in both pre- and post-chemotherapy plasma samples.
- the treatment is selected from a two-agent combination of FOLFOXIRI or FOLFOX and bevacizumab (BEV).
- the treatment with the two agents is concurrent.
- the treatment with the two agents is consecutive.
- the treatment is first-line treatment of mCRC.
- the method involves a step of comparing the mutation status of genes from Table 1 in matched tissue sample and plasma sample collected prior to the commencement of therapy (baseline samples). The comparison revealed a concordance rate of 83% across all genes and 91.5%-100% for known mCRC related biomarkers.
- the invention comprises the use of individual biomarkers to predict a patient's response to chemotherapy.
- somatic mutation predictors of mCRC patient response to cytotoxic chemotherapies in the first line setting.
- the inventors have evaluated a series of somatic mutations for predictive value as shown in Table 2.
- treatment A is concurrent treatment with FOLFOXIRI-bevacizumab (cFOLFOXIRI-BEV)
- treatment B is sequential treatment with FOLFOXIRI-bevacizumab (sFOLFOXIRI-BEV)
- treatment C is treatment with FOLFOX-bevacizumab (FOLFOXI-BEV).
- the inventors have devised a method of using RAS mutation status to prescribe a treatment regimen. Surprisingly, the inventors have found that RAS wild-type patients and KRAS wild-type patients (as determined by applying the mutation test of the invention to pre-induction plasma samples) showed significantly longer progression-free survival (PFS) in both cFOLFOXIRI-BEV (A) and sFOLFOXIRI-BEV (B) arms versus FOLFOX-BEV (C) ( FIG. 2 ).
- PFS progression-free survival
- treatment A is concurrent treatment with FOLFOXIRI-bevacizumab (cFOLFOXIRI-BEV)
- treatment B is sequential treatment with FOLFOXIRI-bevacizumab (sFOLFOXIRI-BEV)
- treatment C is treatment with FOLFOX-bevacizumab (FOLFOXI-BEV).
- the inventors also saw this result using genotyping of tissue samples. This was not seen in RAS or KRAS mutant patients.
- the invention comprises testing a patient's sample for mutations in the RAS gene (KRAS and NRAS) or KRAS gene prior to commencement of chemotherapy.
- the pre-treatment sample is a tumor tissue sample.
- the sample is blood sample.
- the treatment selected from consecutive and sequential FOLFOXIRI-bevacizumab.
- the invention is a method of treating a patient with metastatic CRC comprising testing a patient's sample for mutations in the RAS gene (KRAS and NRAS) or KRAS gene and if no mutations are found, administering therapy selected from consecutive and sequential FOLFOXIRI-bevacizumab.
- the inventors have devised a method of using BRAF mutation status to prescribe a treatment regimen.
- the inventors found that BRAF wild-type patients (as determined by applying the mutation test of the invention to pre-induction plasma samples) showed significantly longer progression-free survival (PFS) in both cFOLFOXIRI-BEV (A) and sFOLFOXIRI-BEV (B) arms versus FOLFOX-BEV (C).
- PFS progression-free survival
- the invention comprises testing a patient's sample for mutations in the BRAF gene prior to commencement of chemotherapy.
- the pre-treatment sample is a tumor tissue sample.
- the sample is blood sample.
- the treatment selected from consecutive and sequential FOLFOXIRI-bevacizumab is selected from consecutive and sequential FOLFOXIRI-bevacizumab.
- the invention is a method of treating a patient with metastatic CRC comprising testing a patient's sample for mutations in the BRAF gene and if no mutations are found, administering therapy selected from consecutive and sequential FOLFOXIRI-bevacizumab.
- the inventors have devised a method of using PIK3CA mutation status to prescribe a treatment regimen.
- the inventors found that PIK3CA wild-type patients (as determined by applying the mutation test of the invention to pre-induction plasma samples) showed significantly longer progression-free survival (PFS) in both cFOLFOXIRI-BEV (A) and sFOLFOXIRI-BEV (B) arms versus FOLFOX-BEV (C).
- PFS progression-free survival
- the inventors also saw this result using genotyping of tissue samples. This was not seen in PIK3CA mutant patients.
- the invention comprises testing a patient's sample for mutations in the PIK3CA gene prior to commencement of chemotherapy.
- the pre-treatment sample is a tumor tissue sample. In other embodiments the sample is blood sample. In some embodiments, the treatment selected from consecutive and sequential FOLFOXIRI-bevacizumab. In some embodiments, the invention is a method of treating a patient with metastatic CRC comprising testing a patient's sample for mutations in the PIK3CA gene and if no mutations are found, administering therapy selected from consecutive and sequential FOLFOXIRI-bevacizumab.
- the inventors have devised a method of using TP53 mutation status to prescribe a treatment regimen.
- the inventors have found that TP53 WT showed no significant treatment differences while TP53 MUT showed longer PFS for cFOLFOXIRI-BEV versus FOLFOX-BEV ( FIG. 3 ).
- the invention comprises testing a patient's sample for mutations in the TP53 gene prior to commencement of chemotherapy.
- the pre-treatment sample is a tumor tissue sample.
- the sample is blood sample.
- the treatment selected from consecutive and sequential FOLFOXIRI-bevacizumab.
- the invention is a method of treating a patient with metastatic CRC comprising testing a patient's sample for mutations in the TP53 gene and if mutations are found, administering therapy selected from consecutive and sequential FOLFOXIRI-bevacizumab.
- the inventors have further devised a method of using mutant allele frequency (mAF) to prescribe a treatment regimen.
- mAF mutant allele frequency
- the invention comprises testing a patient's sample to determine mutant allele frequencies (mAF) in cancer associated genes prior to commencement of chemotherapy.
- the cancer associated genes are those listed in Table 1.
- the pre-treatment sample is a tumor tissue sample.
- the sample is blood sample.
- the treatment selected from consecutive and sequential FOLFOXIRI-bevacizumab.
- the invention is a method of treating a patient with metastatic CRC comprising testing the patient's sample for testing the patient's sample to determine mutant allele frequencies (mAF) in cancer associated genes and if the frequencies are below the median observed in mCRC patients, administering therapy selected from consecutive and sequential FOLFOXIRI-bevacizumab.
- mAF mutant allele frequencies
- the invention further includes a step of improving the biomarker panel based on the results obtained from the clinical samples.
- the invention includes the steps of analyzing the correlation between the presence of a biomarker in the cell-free DNA and response to therapy.
- the biomarkers showing a predictive correlation are to be included in the panel predicting response to particular therapy.
- the biomarkers not showing a statistically significant predictive correlation are to be excluded from the panel predicting response to the therapy.
- the invention includes a step of identifying the patient as likely or not likely to respond to a therapy regimen.
- the identification is based on whether the mutations in the biomarkers of the panel were found during the sequencing step. In some embodiments, several mutations, e.g., mutations in 1, 2, 3, 4 or more biomarkers are found while no mutations in other biomarkers are found.
- the method includes an analysis algorithm for scoring the mutations identified during the sequencing step.
- the algorithm may contain steps of mutation detection, mutation frequency scoring, error correction (including deduplication, using barcodes to eliminate errors) and final determination whether the sample is mutation-positive.
- the sample is scored as mutation-positive for a particular biomarker from the panel when the frequency of a mutated allele (variant allele frequency, VAF) exceeds a certain threshold.
- the threshold is 5% but other thresholds may be used based on the condition of the sample. For example, a tumor sample with low tumor content may have a lower threshold (e.g., ⁇ 5% of mutant allele frequency, VAF) for the sample to be scored as mutation-positive.
- the algorithm also accounts for the germ-line variations in the biomarkers. For example, a biomarker known to have high level of variation in the germline (>1% ExAC, FIG. 1 ) may not be scored as mutant.
- This invention advances the field of mCRC treatment management of patients by identifying gene mutations or mutation allele fractions as a method to predict progression free survival in response to a therapy regimen.
- the method is applicable to metastatic CRC patients and, since these chemotherapeutic agents are also used in stage II/III patients, the method may be applicable to these stages as well.
- Example 1 Using cell-free tumor DNA in metastatic colorectal cancer (mCRC) patients to predict efficacy of therapies
- NGS next-generation sequencing
- STEAM (NCT01765582) evaluated the efficacy and safety of concurrent (c) and sequential (s) FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for first-line treatment of mCRC.
- Matched baseline tissue and pre-induction plasma showed a concordance rate of 83% across all genes and 91.5%-100% for known mCRC related biomarkers.
- Four mutation classes including single-nucleotide variants (SNVs), indels, copy number amplifications (CNAs) and fusions were identified. SNVs and indels were called in tissue and plasma at allele frequencies of 5% and 0.25% respectively.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention is a method of predicting response to therapy in a colorectal cancer patient, the method comprising analysis of circulating tumor DNA from a patient's sample.
Description
- This patent application is a continuation of International Patent Application No. PCT/EP2018/052751 filed Feb. 5, 2018, which claims priority to and the benefit of U.S. Provisional Application No. 62/455,994, filed Feb. 7, 2017. Each of the above patent applications is incorporated herein by reference as if set forth in its entirety.
- The invention relates to the field of oncology. More specifically, the invention relates to the field of nucleic acid-based testing of cancer patients.
- It is important to provide effective therapy to metastatic colorectal cancer (mCRC) patients as they have poor 5-year survival. Currently, mCRC patients receive either targeted anti-EGFR therapy plus chemotherapy based on RAS wildtype status or all comers are eligible for anti-angiogenesis plus chemotherapy. Many of the CRC patients are diagnosed with metastatic disease after progression from earlier stage disease. For some patients, a tissue sample from the earlier stage is not available or does not represent the patient's current disease state. Many patients newly diagnosed with mCRC are considered inoperable. There is a need for a reliable way to access the tumor content of the patients for whom a tumor sample is not available in order to design proper therapy.
- In some embodiments, the invention is a method for identifying a colorectal cancer patient in stage II, III or IV as likely to positively respond to a therapy regimen with increased progression-free survival (PFS), the method comprising the steps of: providing a cell-free blood sample obtained from the patient; determining the sequence of at least a portion of each of the biomarkers listed in Table 1; measuring the frequency of mutant alleles; identifying the patient as likely to positively respond to a therapy regimen if the frequency of mutant alleles is below a median documented for colorectal cancer patients at the same stage; or identifying the patient as not likely to positively respond to a therapy regimen if the frequency of mutant alleles is above a median documented for colorectal cancer patients at the same stage. The patient can be a stage II, III or IV colorectal cancer patient. In some embodiments, the method further comprises a step of administering therapy if the patient is identified as likely to positively respond to a therapy regimen. The therapy regimen may be treatment with FOLFOXIRI-bevacizumab or treatment FOLFOX-bevacizumab. The treatment with FOLFOXIRI-bevacizumab may be concurrent or sequential.
- In some embodiments, the invention is a method for identifying a colorectal cancer patient in stage II, III or IV as likely to positively respond to a therapy regimen with increased progression-free survival (PFS), the method comprising the steps of: providing a cell-free blood sample obtained from the patient; determining the mutation status of one or more genes selected from KRAS, BRAF, TP53 and PIK3CA; identifying the patient as likely to positively respond to a therapy regimen if the genes KRAS, BRAF and PIK3CA are wild-type and gene TP53 is mutant; or identifying the patient as not likely to positively respond to a therapy regimen if the genes KRAS, BRAF and PIK3CA are mutant and gene TP53 is wild-type. The therapy regimen is selected from concurrent and sequential FOLFOXIRI-bevacizumab.
- In some embodiments, the invention is a method of treatment of a colorectal cancer patient in stage II, III or IV comprising the steps of: providing a cell-free blood sample obtained from the patient; determining the sequence of at least a portion of each of the biomarkers listed in Table 1; measuring the frequency of mutant alleles; identifying the patient as likely to positively respond to a therapy regimen if the frequency of mutant alleles is below a median documented for colorectal cancer patients at the same stage; or identifying the patient as not likely to positively respond to a therapy regimen if the frequency of mutant alleles is above a median documented for colorectal cancer patients at the same stage; administering the therapy regimen to the patient identified as likely to positively respond to the therapy. The patient may be a stage II, III or IV colorectal cancer patient. In some embodiments, the therapy regimen is selected from concurrent and sequential FOLFOXIRI-bevacizumab.
- In some embodiments, the invention is a computer system designed to implement an algorithm for detecting mutations in a sample from colorectal cancer patient, wherein the algorithm analyses sequencing data on biomarkers from Table 1 and contains one or more steps selected from mutation detection, mutation frequency scoring, controlling for germ-line variation, error correction and final determination whether the sample is mutation-positive.
-
FIG. 1 illustrates the design of the therapy response prediction study. -
FIG. 2 illustrates Kaplan Meier graphs comparing treatment of RAS wild-type patients. -
FIG. 3 illustrates Kaplan Meier graphs comparing treatment of TP53 mutant patients. -
FIG. 4 illustrates Kaplan Meier graphs comparing treatment outcomes of patients with different mutation burdens (mutant allele frequencies, AF). - The following definitions are not limiting but merely aid in understanding this disclosure.
- The term “RFS” is used herein to describe the time of Recurrence Free Survival for a patient.
- The term “TTR” is used herein to describe the Total Time to Recurrence for a patient.
- The term “OS” is used herein to describe the time of Overall Survival for a patient.
- The term “CAPP-Seq” is used herein to describe a method of analyzing cell-free tumor DNA in a patient disclosed in U.S. patent application Ser. Nos. 14/209,807, 14/774,518 and International Application Ser. No. PCT/US2015/049838 titled “Identification and Use of Circulating Tumor Markers.”
- The term “R0 patient” is used herein to describe a patient having clear histological margins from resected tissue.
- The term “R1 patient” is used herein to describe a patient having microscopic residual disease in surgically resected tissue.
- The term “circulating tumor DNA (ctDNA)” is used herein to describe a portion of cell-free DNA found in human blood plasma or serum that originates from the tumor. Circulating tumor DNA is distinguished from non-tumor DNA by the mutations characteristic of the tumor. In the context of the present invention, detecting ctDNA means detecting mutated cell-free DNA.
- The term “biomarker” is used herein to describe a nucleotide sequence that contains information relevant to the biological or clinical phenomenon. For example, the information may be a mutation status of the sequence. The biomarker can be a gene (including coding sequence, regulatory sequence, intron or a splice site) or an intergenic region. The clinical phenomenon can be the presence of malignant cells, e.g., tumor cells in a patient's sample.
- The invention describes methods of selecting a treatment regimen for a colorectal cancer (CRC) patient including a metastatic colorectal cancer (mCRC) patient.
- In some embodiments, the invention uses a biomarker panel to identify somatic mutations and mutation burden in cancer-related genes by next-generation sequencing (NGS). In some embodiments, the invention utilized a blood sample from a patient. The sample can include any fraction of blood, e.g., serum or plasma, which contains cell-free DNA including circulating tumor DNA (cfDNA or ctDNA). In some embodiments, the sample is taken serially at various times during treatment, e.g., before and after surgery or before, after and during a chemotherapy regimen. In some embodiments, tissue sample is available for comparison with the blood sample. The tissue or blood sample can be collected by a suitable means that preserves the DNA therein, including formalin-fix paraffin-embedding (FFPE), fresh frozen tissue or blood tissue collected in a preservative medium.
- In some embodiments, the invention utilizes a biomarker panel, including a gene panel or a mutation panel or a somatic variant panel. The mutations may include single-nucleotide variations (SNVs), deletions and insertions (in-dels) that correspond to on-sense missense and frame-shift mutations if they occur in the coding regions of genes. Other types of mutations include gene fusions and translocations. The selection, size and content of such panels has been described e.g., in U.S. patent application Ser. Nos. 14/209,807, 14/774,518 and International app. No. PCT/US2015/049838 titled “Identification and Use of Circulating Tumor Markers.” In some embodiments, the invention includes determining the sequence of the biomarkers in the panel, e.g., the genes listed in Table 1. In some embodiments, the entire sequence of a gene is determined. In other embodiments, the entire coding sequence of a gene is determined. In other embodiments, only the sequence of a portion of the gene known to undergo mutagenesis in cancer is determined. In yet other embodiments, the biomarker is not associated with a coding sequence but is associated with a regulatory sequence or a sequence of unknown function known to be mutated in human tumors.
- In the context of the present invention, the sequence of a biomarker can be determined via any suitable method known in the art. The suitable method would have sufficient accuracy, e.g., sensitivity and specificity to detect rare sequences with a low rate of errors. In some embodiments, the sequencing method includes an error correction step, such as use of molecular barcodes, error stereotyping and other chemical or computation methods of error suppression as described e.g., in see the patent applications “Identification and Use of Circulating Tumor Markers”, supra. The sequencing method may include a massively parallel sequencing method, including an array based sequencing (Illumina, San Diego, Calif.), an emulsion-based sequencing (ThermoFisher, Waltham, Mass.) an optical measurement based sequencing (Pacific BioSciences, Menlo Park, Calif.) or a nanopore-based sequencing (Roche Sequencing Solutions, Santa Clara, Calif.).
- In some embodiments, the invention utilizes a biomarker panel, such as AVENIO• ctDNA Analysis Kit (Roche Sequencing Solutions, Inc., Pleasanton, Calif.) that is capable of analyzing the blood of patients after surgery to identify whether patients have circulating tumor DNA (ctDNA). The composition of the biomarker panel in AVENIO® ctDNA Analysis Kit (expanded panel) is shown in Table 1.
-
TABLE 1 Composition of the biomarker panel APC KRAS ABL1 FGFR3 JAK3 RAF1 BRCA1 MET AKT1 FLT1 KDR RNF43 BRCA2 TP53 AKT2 FLT3 MAP2K1 TERT promoter EGFR KIT ARAF FLT4 MAP2K2 TSC1 ERBB2 NRAS CDK6 GATA3 MTOR TSC2 ALK PDGFRA CSF1R GNA11 NFE2L2 PTEN BRAF RET CTNNB1 GNAQ NTRK1 RB1 DPYD ROS1 DDR2 GNAS PDGFRB SMAD4 AR MSH2 EZH2 IDH1 PIK3CA SMO CCND1 MSH6 FGFR1 IDH2 PIK3R1 STK11 CCND2 NF2 FGFR2 JAK2 PTCH1 VHL CCND3 PDCD1LG2 CDK4 ESR1 KEAP1 UGT1A1 CD274 PMS2 CDKN2A FBXW7 MLH1 - In some embodiments, a panel of 77 genes listed in Table 1 is used. In some embodiments, the mutation status is determined in both pre- and post-chemotherapy plasma samples. In some embodiments, the treatment is selected from a two-agent combination of FOLFOXIRI or FOLFOX and bevacizumab (BEV). In some embodiments, the treatment with the two agents is concurrent. In some embodiments, the treatment with the two agents is consecutive. In some embodiments, the treatment is first-line treatment of mCRC.
- In some embodiments, the method involves a step of comparing the mutation status of genes from Table 1 in matched tissue sample and plasma sample collected prior to the commencement of therapy (baseline samples). The comparison revealed a concordance rate of 83% across all genes and 91.5%-100% for known mCRC related biomarkers.
- In some embodiments, the invention comprises the use of individual biomarkers to predict a patient's response to chemotherapy. Until the present disclosure, there have been no known somatic mutation predictors of mCRC patient response to cytotoxic chemotherapies in the first line setting. The inventors have evaluated a series of somatic mutations for predictive value as shown in Table 2. In the table, treatment A is concurrent treatment with FOLFOXIRI-bevacizumab (cFOLFOXIRI-BEV), treatment B is sequential treatment with FOLFOXIRI-bevacizumab (sFOLFOXIRI-BEV) and treatment C is treatment with FOLFOX-bevacizumab (FOLFOXI-BEV).
-
TABLE 2 Effect of specific mutations on treatment efficacy Tissue (N = 118) Pre-Tx Plasma (N = 118) Med PFS PFS Med PFS PFS Gene Comparison N (mo) HR p-val N (mo) HR p-val KRAS WT v MT 60/58 12.8/9.5 0.801 0.3174 70/48 11.5/9.5 0.839 0.4280 A v C in MT 15/16 16.9/8.1 0.446 0.1021 14/14 16.9/8.1 0.400 0.0929 B v C in MT 27/16 8.3/8.1 0.950 0.8855 20/14 7.6/8.1 1.045 0.9164 A v C in WT 21/21 13.4/8.1 0.450 0.0594 22/23 13.4/8.1 0.472 0.0548 B v C in WT 18/21 16.1/8.1 0.363 0.0238 25/23 13.6/8.1 0.431 0.0248 RAS* WT v MT 55/63 13.4/9.5 0.786 0.2827 65/53 12.2/9.5 0.784 0.2668 A v C in MT 17/19 15.3/8.1 0.471 0.1052 16/17 15.3/8.1 0.502 0.1547 B v C in MT 27/19 8.3/8.1 1.008 0.9803 20/17 7.6/8.1 1.108 0.7931 A v C in WT 19/18 13.4/8.5 0.387 0.0382 20/20 18.4/8.5 0.380 0.0233 B v C in WT 18/18 16.1/8.5 0.323 0.0152 25/20 13.6/8.5 0.386 0.0142 BRAF WT v MT 113/5 10.9/6.2 0.492 0.1692 113/5 10.9/6.2 0.492 0.1692 A v C in MT 3/1 8.0/NA NA NA 3/1 8.0/NA NA NA B v C in MT 1/1 3.3/NA NA NA 1/1 3.3/NA NA NA A v C in WT 33/36 16.9/8.1 0.444 0.0101 33/36 16.9/8.1 0.444 0.0101 B v C in WT 44/36 11.5/8.1 0.667 0.1244 44/36 11.5/8.1 0.667 0.1244 PIK3CA WT v MT 100/18 11.2/8.1 0.650 0.1602 101/17 10.9/9.1 0.679 0.2208 A v C in MT 6/5 15.3/8.1 0.299 0.2282 5/4 15.3/8.1 0.611 0.6473 B v C in MT 7/5 7.4/8.1 1.280 0.7828 8/4 7.4/8.1 1.943 0.4950 A v C in WT 30/32 13.4/8.8 0.480 0.0243 31/33 16.9/8.1 0.458 0.0160 B v C in WT 38/32 12.8/8.8 0.590 0.0656 37/33 12.2/8.1 0.590 0.0641 TP53 WT v MT 43/75 10.4/10.9 0.867 0.5407 47/71 10.4/11.2 0.919 0.7117 A v C in MT 26/23 16.9/8.1 0.402 0.0161 25/19 16.9/7.7 0.356 0.0098 B v C in MT 26/23 11.5/8.1 0.559 0.0892 27/19 12.2/7.7 0.514 0.0627 A v C in WT 10/14 15.3/8.8 0.444 0.1682 11/18 15.3/9.5 0.478 0.1655 B v C in WT 19/14 10.7/8.8 1.002 0.9965 18/18 10.7/9.5 0.965 0.9326 *RAS is a combination of NRAS and KRAS - The inventors have devised a method of using RAS mutation status to prescribe a treatment regimen. Surprisingly, the inventors have found that RAS wild-type patients and KRAS wild-type patients (as determined by applying the mutation test of the invention to pre-induction plasma samples) showed significantly longer progression-free survival (PFS) in both cFOLFOXIRI-BEV (A) and sFOLFOXIRI-BEV (B) arms versus FOLFOX-BEV (C) (
FIG. 2 ). InFIGS. 2, 3 and 4 , as in Table 2, treatment A is concurrent treatment with FOLFOXIRI-bevacizumab (cFOLFOXIRI-BEV), treatment B is sequential treatment with FOLFOXIRI-bevacizumab (sFOLFOXIRI-BEV) and treatment C is treatment with FOLFOX-bevacizumab (FOLFOXI-BEV). The inventors also saw this result using genotyping of tissue samples. This was not seen in RAS or KRAS mutant patients. In some embodiments, the invention comprises testing a patient's sample for mutations in the RAS gene (KRAS and NRAS) or KRAS gene prior to commencement of chemotherapy. In some embodiments, the pre-treatment sample is a tumor tissue sample. In other embodiments the sample is blood sample. In some embodiments, the treatment selected from consecutive and sequential FOLFOXIRI-bevacizumab. In some embodiments, the invention is a method of treating a patient with metastatic CRC comprising testing a patient's sample for mutations in the RAS gene (KRAS and NRAS) or KRAS gene and if no mutations are found, administering therapy selected from consecutive and sequential FOLFOXIRI-bevacizumab. - Further, the inventors have devised a method of using BRAF mutation status to prescribe a treatment regimen. The inventors found that BRAF wild-type patients (as determined by applying the mutation test of the invention to pre-induction plasma samples) showed significantly longer progression-free survival (PFS) in both cFOLFOXIRI-BEV (A) and sFOLFOXIRI-BEV (B) arms versus FOLFOX-BEV (C). The inventors also saw this result using genotyping of tissue samples. This was not seen in BRAF mutant patients. In some embodiments, the invention comprises testing a patient's sample for mutations in the BRAF gene prior to commencement of chemotherapy. In some embodiments, the pre-treatment sample is a tumor tissue sample. In other embodiments the sample is blood sample. In some embodiments, the treatment selected from consecutive and sequential FOLFOXIRI-bevacizumab. In some embodiments, the invention is a method of treating a patient with metastatic CRC comprising testing a patient's sample for mutations in the BRAF gene and if no mutations are found, administering therapy selected from consecutive and sequential FOLFOXIRI-bevacizumab.
- Further, the inventors have devised a method of using PIK3CA mutation status to prescribe a treatment regimen. The inventors found that PIK3CA wild-type patients (as determined by applying the mutation test of the invention to pre-induction plasma samples) showed significantly longer progression-free survival (PFS) in both cFOLFOXIRI-BEV (A) and sFOLFOXIRI-BEV (B) arms versus FOLFOX-BEV (C). The inventors also saw this result using genotyping of tissue samples. This was not seen in PIK3CA mutant patients. In some embodiments, the invention comprises testing a patient's sample for mutations in the PIK3CA gene prior to commencement of chemotherapy. In some embodiments, the pre-treatment sample is a tumor tissue sample. In other embodiments the sample is blood sample. In some embodiments, the treatment selected from consecutive and sequential FOLFOXIRI-bevacizumab. In some embodiments, the invention is a method of treating a patient with metastatic CRC comprising testing a patient's sample for mutations in the PIK3CA gene and if no mutations are found, administering therapy selected from consecutive and sequential FOLFOXIRI-bevacizumab.
- Yet further, the inventors have devised a method of using TP53 mutation status to prescribe a treatment regimen. The inventors have found that TP53 WT showed no significant treatment differences while TP53 MUT showed longer PFS for cFOLFOXIRI-BEV versus FOLFOX-BEV (
FIG. 3 ). In some embodiments, the invention comprises testing a patient's sample for mutations in the TP53 gene prior to commencement of chemotherapy. In some embodiments, the pre-treatment sample is a tumor tissue sample. In other embodiments the sample is blood sample. In some embodiments, the treatment selected from consecutive and sequential FOLFOXIRI-bevacizumab. In some embodiments, the invention is a method of treating a patient with metastatic CRC comprising testing a patient's sample for mutations in the TP53 gene and if mutations are found, administering therapy selected from consecutive and sequential FOLFOXIRI-bevacizumab. - The findings described above and illustrated in Table 2 underscore the unpredictability of the mutations in oncogenes and antioncogenes. While the wild-type status of the RAS, BRAF and PIK3CA oncogenes has a positive effect on response, the wild-type status of the TP53 antioncogene has no positive effect. At the same time, the mutant status of the RAS, BRAF and PIK3CA oncogenes has no positive effect on response to therapy, while mutant status of the TP53 antioncogene has a positive effect on response to therapy. Further underscoring unpredictability, the mutation status is more relevant to some types of therapy than others, e.g., FOLFOXIRI-bevacizumab but not FOLFOX-bevacizumab.
- The inventors have further devised a method of using mutant allele frequency (mAF) to prescribe a treatment regimen. As shown in Table 3 and
FIG. 4 , the inventors have discovered that patients with a pre-induction mAF below the median had longer PFS compared to patients with mAF above the median (13.4 vs 9.5 mo, HR 0.49, p=0.002). A similar trend was seen for overall survival (OS). Within the below median mAF group, longer PFS was observed in patients treated with cFOLFOXIRI-BEV versus FOLFOX-BEV (25.2 vs 9.5 mo, HR 0.34, p=0.020). In contrast, no differences in PFS were observed in the treatment arms in the above median mAF group. Patients with a post-induction mAF below the median had longer PFS compared to patients with mAF above the median (15.3 vs 8.1 mo, HR 0.51, p=0.0064). In some embodiments, the invention comprises testing a patient's sample to determine mutant allele frequencies (mAF) in cancer associated genes prior to commencement of chemotherapy. In some embodiments, the cancer associated genes are those listed in Table 1. In some embodiments, the pre-treatment sample is a tumor tissue sample. In other embodiments the sample is blood sample. In some embodiments, the treatment selected from consecutive and sequential FOLFOXIRI-bevacizumab. In some embodiments, the invention is a method of treating a patient with metastatic CRC comprising testing the patient's sample for testing the patient's sample to determine mutant allele frequencies (mAF) in cancer associated genes and if the frequencies are below the median observed in mCRC patients, administering therapy selected from consecutive and sequential FOLFOXIRI-bevacizumab. - In some embodiments, the invention further includes a step of improving the biomarker panel based on the results obtained from the clinical samples. In some embodiments, the invention includes the steps of analyzing the correlation between the presence of a biomarker in the cell-free DNA and response to therapy. The biomarkers showing a predictive correlation are to be included in the panel predicting response to particular therapy. The biomarkers not showing a statistically significant predictive correlation are to be excluded from the panel predicting response to the therapy.
- The invention includes a step of identifying the patient as likely or not likely to respond to a therapy regimen. The identification is based on whether the mutations in the biomarkers of the panel were found during the sequencing step. In some embodiments, several mutations, e.g., mutations in 1, 2, 3, 4 or more biomarkers are found while no mutations in other biomarkers are found.
- In some embodiments, the method includes an analysis algorithm for scoring the mutations identified during the sequencing step. The algorithm may contain steps of mutation detection, mutation frequency scoring, error correction (including deduplication, using barcodes to eliminate errors) and final determination whether the sample is mutation-positive. In some embodiments, the sample is scored as mutation-positive for a particular biomarker from the panel when the frequency of a mutated allele (variant allele frequency, VAF) exceeds a certain threshold. In some embodiments, the threshold is 5% but other thresholds may be used based on the condition of the sample. For example, a tumor sample with low tumor content may have a lower threshold (e.g., <5% of mutant allele frequency, VAF) for the sample to be scored as mutation-positive. In some embodiments, the algorithm also accounts for the germ-line variations in the biomarkers. For example, a biomarker known to have high level of variation in the germline (>1% ExAC,
FIG. 1 ) may not be scored as mutant. - This invention advances the field of mCRC treatment management of patients by identifying gene mutations or mutation allele fractions as a method to predict progression free survival in response to a therapy regimen. The method is applicable to metastatic CRC patients and, since these chemotherapeutic agents are also used in stage II/III patients, the method may be applicable to these stages as well.
- In this example, the next-generation sequencing based AVENIO® ctDNA Expanded Kit (Roche Sequencing Solutions, Pleasanton, Calif.) was used to identify somatic mutations and mutation burden in 77 cancer-related genes by next-generation sequencing (NGS) in both pre- and post-induction plasma samples (n=118 for both groups) from STEAM. STEAM (NCT01765582) evaluated the efficacy and safety of concurrent (c) and sequential (s) FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for first-line treatment of mCRC. Matched baseline tissue and pre-induction plasma showed a concordance rate of 83% across all genes and 91.5%-100% for known mCRC related biomarkers. Four mutation classes including single-nucleotide variants (SNVs), indels, copy number amplifications (CNAs) and fusions were identified. SNVs and indels were called in tissue and plasma at allele frequencies of 5% and 0.25% respectively.
- Overall, patients with a pre-induction mutant allele frequency (mAF) below the median had longer PFS compared to patients with mAF above the median (13.4 vs 9.5 mo, HR 0.49, p=0.002). A similar trend was seen for overall survival (OS). Within the below median mAF group, longer PFS was observed in patients treated with cFOLFOXIRI-BEV versus FOLFOX-BEV (25.2 vs 9.5 mo, HR 0.34, p=0.020). In contrast, no differences in PFS were observed in the treatment arms in the above median mAF group. Patients with a post-induction mAF below the median had longer PFS compared to patients with mAF above the median (15.3 vs 8.1 mo, HR 0.51, p=0.0064).
Claims (10)
1. A method for identifying a colorectal cancer patient in stage II, III, or IV as likely to positively respond to an anti-tumor therapy regimen with increased progression-free survival (PFS), wherein the method comprises the steps of:
(a) providing a cell-free blood sample obtained from the patient;
(b) determining the sequence of at least a portion of each of the biomarkers listed in Table 1;
(c) measuring the frequency of mutant alleles; and
(d)(i) identifying the patient as likely to positively respond to a therapy regimen if the frequency of mutant alleles is below a median documented for colorectal cancer patients at the same stage; or
(d)(ii) identifying the patient as not likely to positively respond to a therapy regimen if the frequency of mutant alleles is above a median documented for colorectal cancer patients at the same stage.
2. The method of claim 1 , wherein the sequences of at least a portion of all of the biomarkers listed in Table 1 are determined.
3. The method of claim 1 , wherein the therapy regimen is selected from treatment with FOLFOXIRI-bevacizumab and treatment with FOLFOX-bevacizumab.
4. The method of claim 3 , wherein the treatment with FOLFOXIRI-bevacizumab is selected from concurrent and sequential.
5. The method of claim 1 , further comprising a step of administering the therapy if the patient is identified as likely to positively respond to the therapy regimen.
6-8. (canceled)
9. A method of treatment of a colorectal cancer patient in stage II, III, or IV, wherein the method comprises the steps of:
(a) providing a cell-free blood sample obtained from the patient;
(b) determining the sequence of at least a portion of each of the biomarkers listed in Table 1;
(c) measuring the frequency of mutant alleles; and
(d)(i) identifying the patient as likely to positively respond to an anti-tumor therapy regimen if the frequency of mutant alleles is below a median documented for colorectal cancer patients at the same stage; or
(d)(ii) identifying the patient as not likely to positively respond to an anti-tumor therapy regimen if the frequency of mutant alleles is above a median documented for colorectal cancer patients at the same stage; and
(e) administering the therapy regimen to the patient identified as likely to positively respond to the therapy regimen.
10. A method of claim 9 , wherein at least a partial sequence of all the biomarkers listed in Table 1 are determined.
11. The method of claim 9 , wherein the therapy regimen is selected from concurrent and sequential FOLFOXIRI-bevacizumab.
12. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/046,565 US20230083203A1 (en) | 2017-02-07 | 2022-10-14 | Non-invasive test to predict response to therapy in colorectal cancer patients |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762455994P | 2017-02-07 | 2017-02-07 | |
PCT/EP2018/052751 WO2018146034A1 (en) | 2017-02-07 | 2018-02-05 | Non-invasive test to predict response to therapy in colorectal cancer patients |
US16/534,272 US11519037B2 (en) | 2017-02-07 | 2019-08-07 | Non-invasive test to predict response to therapy in colorectal cancer patients |
US18/046,565 US20230083203A1 (en) | 2017-02-07 | 2022-10-14 | Non-invasive test to predict response to therapy in colorectal cancer patients |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/534,272 Continuation US11519037B2 (en) | 2017-02-07 | 2019-08-07 | Non-invasive test to predict response to therapy in colorectal cancer patients |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230083203A1 true US20230083203A1 (en) | 2023-03-16 |
Family
ID=61187310
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/534,272 Active 2039-06-21 US11519037B2 (en) | 2017-02-07 | 2019-08-07 | Non-invasive test to predict response to therapy in colorectal cancer patients |
US18/046,565 Pending US20230083203A1 (en) | 2017-02-07 | 2022-10-14 | Non-invasive test to predict response to therapy in colorectal cancer patients |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/534,272 Active 2039-06-21 US11519037B2 (en) | 2017-02-07 | 2019-08-07 | Non-invasive test to predict response to therapy in colorectal cancer patients |
Country Status (3)
Country | Link |
---|---|
US (2) | US11519037B2 (en) |
EP (1) | EP3580360A1 (en) |
WO (1) | WO2018146034A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4369356A2 (en) | 2018-11-30 | 2024-05-15 | Caris MPI, Inc. | Next-generation molecular profiling |
CA3163319A1 (en) | 2019-12-02 | 2021-06-10 | Caris Mpi, Inc. | Pan-cancer platinum response predictor |
CN111690747B (en) * | 2020-07-03 | 2023-04-14 | 南京世和医疗器械有限公司 | Combined marker related to early and medium colon cancer, detection kit and detection system |
CN113278611B (en) * | 2021-03-07 | 2022-11-25 | 华中科技大学同济医学院附属协和医院 | Capture sequencing probes and uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160032396A1 (en) * | 2013-03-15 | 2016-02-04 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and Use of Circulating Nucleic Acid Tumor Markers |
-
2018
- 2018-02-05 EP EP18703757.7A patent/EP3580360A1/en active Pending
- 2018-02-05 WO PCT/EP2018/052751 patent/WO2018146034A1/en unknown
-
2019
- 2019-08-07 US US16/534,272 patent/US11519037B2/en active Active
-
2022
- 2022-10-14 US US18/046,565 patent/US20230083203A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018146034A1 (en) | 2018-08-16 |
US20190360060A1 (en) | 2019-11-28 |
US11519037B2 (en) | 2022-12-06 |
EP3580360A1 (en) | 2019-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230083203A1 (en) | Non-invasive test to predict response to therapy in colorectal cancer patients | |
Singhi et al. | Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers | |
Lamberti et al. | Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer | |
Siravegna et al. | Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients | |
Li et al. | Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications | |
Simbolo et al. | High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas | |
AU2014227883B2 (en) | Classification and actionability indices for lung cancer | |
Park et al. | Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma | |
Christopoulos et al. | Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing | |
Shimada et al. | Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer | |
CN111684078B (en) | Methods for predicting response to treatment by assessing tumor genetic heterogeneity | |
Armengol et al. | Driver gene mutations in stools of colorectal carcinoma patients detected by targeted next-generation sequencing | |
US11821041B2 (en) | Non-invasive test to predict recurrence of colorectal cancer | |
Li et al. | Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencing | |
Abdayem et al. | Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer | |
Thomas et al. | Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit | |
Zhu et al. | Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non–small-cell Lung Cancer | |
Li et al. | NGS-based oncogenic mutations analysis in advanced colorectal cancer patients improves targeted therapy prediction | |
Sihag et al. | The role of the TP53 pathway in predicting response to neoadjuvant therapy in esophageal adenocarcinoma | |
Fischer et al. | Mutation analysis of nine chordoma specimens by targeted next-generation cancer panel sequencing | |
Park et al. | Genetic characterization of molecular targets in Korean patients with gastrointestinal stromal tumors | |
Reissig et al. | Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer | |
Lin et al. | Oxaliplatin-based chemotherapy might provide longer progression-free survival in KRAS mutant metastatic colorectal cancer | |
US20200399711A1 (en) | Method of predicting response to therapy by assessing tumor genetic heterogeneity | |
Teleanu et al. | Targeted therapy of advanced parathyroid carcinoma guided by genomic and transcriptomic profiling |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |